Physician profile
Fuad Zayed
NPI 1356342190
$2,321.75
in general payments reported to CMS, 2019-2025
13 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $458 · 2021: $805 · 2022: $281 · 2023: $230 · 2024: $185 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $535 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $534.56 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,004.54 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $343.83 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Medtronic, INC. | $235.12 | 2021 | |
| Janssen Pharmaceuticals, INC | $210.45 | 2019-2020 | |
| Pfizer INC. | $205.52 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $151.69 | 2022-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.08 | 2024-2025 | Jardiance |
| Abbott Laboratories | $28.35 | 2024-2025 | Freestyle Libre 3 |
| Amgen INC. | $22.34 | 2023 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $21.76 | 2021 | |
| Sumitomo Pharma America, INC. | $20.28 | 2024 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $16.42 | 2023 | |
| Merck Sharp & Dohme LLC | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fuad Zayed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.